Optimized CSP variants and related methods
By optimizing the nucleotide content in polyribonucleotides encoding plasmodium CSP polypeptides, the irregular peak issues are resolved, ensuring reliable production and delivery of plasmodium CSP antigens for malaria vaccines.
JP2026517790APending Publication Date: 2026-06-02BIONTECH SE
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- BIONTECH SE
- Filing Date
- 2024-05-02
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517790000001_ABST
Abstract
This disclosure provides compositions (e.g., pharmaceutical compositions) and related technologies (e.g., their components and / or related methods) for the delivery of plasmodium circumsporozoite (CSP) protein antigens. In particular, this disclosure provides polyribonucleotides comprising coding sequences encoding full-length plasmodium CSP polypeptides. In some embodiments, the full-length plasmodium CSP polypeptide comprises the N-terminal domain of plasmodium CSP, and the coding sequences of the polyribonucleotides encoding the full-length plasmodium CSP polypeptide have a specific nucleotide content provided herein.
Need to check novelty before this filing date? Find Prior Art